Home / Legal High News Laws / Federal Bill HR 1254 due after July 9th, effective 48 hours later.
Heads up to all Smoking Blend / Herbal Incense / Spice Incense users HR-1254 also known as the synthetic drug control act, has been amended into a larger FDA bill known as S.3187 which includes a copy paste version of the HR-1254 Bill at the very end. It has passed the House and Senate votes and is now due to be signed by the President on or shortly after July 9th, 2012 the bill will come into full effect 48 hrs after the signing. Be aware that if you have purchased Herbal Blends prior to this time period it is very possible that they contained banned substances.

Federal Bill HR 1254 due after July 9th, effective 48 hours later.

Heads up to all Smoking Blend / Herbal Incense / Spice Incense users HR-1254 also known as the synthetic drug control act, has been amended into a larger FDA bill known as S.3187 which includes a copy paste version of the HR-1254 Bill at the very end.

It has passed the House and Senate votes and is now due to be signed by the President on or shortly after July 9th, 2012 the bill will come into full effect 48 hrs after the signing.

Be aware that if you have purchased Herbal Blends prior to this time period it is very possible that they contained banned substances.

You can read S. 3187 for yourself here.

You can track the progress of S. 3187 here.

 

Don’t freak out however, many big players in the market have been well aware of the coming changes with bill HR-1254 as a good heads up. Therefore, it is possible that if your supplier is a reputable or more likely an intelligent one he/she has already made the switch over to post ban legal compounds. However, it is also very likely that they have not as many herbal blends suppliers site on a sizeable amount of product at any given time and are likely trying to get rid of there products.

Be aware of super-sales or heavily discounted Herbal Incense on Smoking Blends sites. These sales/promotions are likely a tactic by the vendor to liquidate the stock before the ban comes into effect. You do not want to get caught with illegal products it could result in as much as 25 years to 30 years for repeat offenders. Be sure to ask for a lab report proving the legality of the product prior to purchasing it, if it

Bill S.3187 is not the first bills to hit the industry, prior to this bill the DEA along with individual states enacted a series of laws outlawing the sale/distribution and production or particular kinds of chemicals that were being used in Herbal Incense. However, the industry as persist and it will persist. There are legal alternatives that are not included int the federal law, namely UR-144 and 5F-UR144 both compounds are structurally different then what is outlined in the bill therefore do not fall under the ban.

As with all legislation, this will not make the illegal products go away. Instead it will merely push these types of products underground, or more dangerously for the consumer vendors will simply lie and copy paste other vendors lab reports all the while selling illegal products.

Observe here is the complete bill found at the bottom of the bill:

Subtitle D—Synthetic Drugs
SEC. 1151. SHORT TITLE.
This subtitle may be cited as the ‘‘Synthetic Drug Abuse Prevention Act of 2012’’.
SEC. 1152. ADDITION OF SYNTHETIC DRUGS TO SCHEDULE I OF THE
CONTROLLED SUBSTANCES ACT.
(a) CANNABIMIMETIC AGENTS.—Schedule I, as set forth in section 202(c) of the Controlled Substances Act (21 U.S.C. 812(c))
is amended by adding at the end the following:
‘‘(d)(1) Unless specifically exempted or unless listed in another
schedule, any material, compound, mixture, or preparation which
contains any quantity of cannabimimetic agents, or which contains
their salts, isomers, and salts of isomers whenever the existence
of such salts, isomers, and salts of isomers is possible within the
specific chemical designation.
‘‘(2) In paragraph (1):
‘‘(A) The term ‘cannabimimetic agents’ means any substance that is a cannabinoid receptor type 1 (CB1 receptor)
agonist as demonstrated by binding studies and functional
assays within any of the following structural classes:
‘‘(i) 2-(3-hydroxycyclohexyl)phenol with substitution at
the 5-position of the phenolic ring by alkyl or alkenyl,
whether or not substituted on the cyclohexyl ring to any
extent. S. 3187—139
‘‘(ii) 3-(1-naphthoyl)indole or 3-(1-
naphthylmethane)indole by substitution at the nitrogen
atom of the indole ring, whether or not further substituted
on the indole ring to any extent, whether or not substituted
on the naphthoyl or naphthyl ring to any extent.
‘‘(iii) 3-(1-naphthoyl)pyrrole by substitution at the
nitrogen atom of the pyrrole ring, whether or not further
substituted in the pyrrole ring to any extent, whether
or not substituted on the naphthoyl ring to any extent.
‘‘(iv) 1-(1-naphthylmethylene)indene by substitution of
the 3-position of the indene ring, whether or not further
substituted in the indene ring to any extent, whether or
not substituted on the naphthyl ring to any extent.
‘‘(v) 3-phenylacetylindole or 3-benzoylindole by substitution at the nitrogen atom of the indole ring, whether
or not further substituted in the indole ring to any extent,
whether or not substituted on the phenyl ring to any extent.
‘‘(B) Such term includes—
‘‘(i) 5-(1,1-dimethylheptyl)-2-[(1R,3S)-3-
hydroxycyclohexyl]-phenol (CP–47,497);
‘‘(ii) 5-(1,1-dimethyloctyl)-2-[(1R,3S)-3-
hydroxycyclohexyl]-phenol (cannabicyclohexanol or CP–
47,497 C8-homolog);
‘‘(iii) 1-pentyl-3-(1-naphthoyl)indole (JWH–018 and
AM678);
‘‘(iv) 1-butyl-3-(1-naphthoyl)indole (JWH–073);
‘‘(v) 1-hexyl-3-(1-naphthoyl)indole (JWH–019);
‘‘(vi) 1-[2-(4-morpholinyl)ethyl]-3-(1-naphthoyl)indole
(JWH–200);
‘‘(vii) 1-pentyl-3-(2-methoxyphenylacetyl)indole (JWH–
250);
‘‘(viii) 1-pentyl-3-[1-(4-methoxynaphthoyl)]indole
(JWH–081);
‘‘(ix) 1-pentyl-3-(4-methyl-1-naphthoyl)indole (JWH–
122);
‘‘(x) 1-pentyl-3-(4-chloro-1-naphthoyl)indole (JWH–
398);
‘‘(xi) 1-(5-fluoropentyl)-3-(1-naphthoyl)indole (AM2201);
‘‘(xii) 1-(5-fluoropentyl)-3-(2-iodobenzoyl)indole
(AM694);
‘‘(xiii) 1-pentyl-3-[(4-methoxy)-benzoyl]indole (SR–19
and RCS–4);
‘‘(xiv) 1-cyclohexylethyl-3-(2-
methoxyphenylacetyl)indole (SR–18 and RCS–8); and
‘‘(xv) 1-pentyl-3-(2-chlorophenylacetyl)indole (JWH–
203).’’.
(b) OTHER DRUGS.—Schedule I of section 202(c) of the Controlled Substances Act (21 U.S.C. 812(c)) is amended in subsection
(c) by adding at the end the following:
‘‘(18) 4-methylmethcathinone (Mephedrone).
‘‘(19) 3,4-methylenedioxypyrovalerone (MDPV).
‘‘(20) 2-(2,5-Dimethoxy-4-ethylphenyl)ethanamine (2C–E).
‘‘(21) 2-(2,5-Dimethoxy-4-methylphenyl)ethanamine (2C–D).
‘‘(22) 2-(4-Chloro-2,5-dimethoxyphenyl)ethanamine (2C–C).
‘‘(23) 2-(4-Iodo-2,5-dimethoxyphenyl)ethanamine (2C–I).
‘‘(24) 2-[4-(Ethylthio)-2,5-dimethoxyphenyl]ethanamine
(2C–T–2).

 

 

 

About admin

2 comments

  1. Pat calhoun

    Hello. Can you send me More information on where it states the bill becomes effective 48 hours after signed. I have read the FDA bill. Thank you. Pat

Leave a Reply

Your email address will not be published. Required fields are marked *

*

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>

High :
Quality :
Price :
Overall Rating :